Liminal BioSciences Inc.

NasdaqCM:LMNL Stock Report

Market Cap: US$13.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Liminal BioSciences Management

Management criteria checks 3/4

Liminal BioSciences' CEO is Bruce Pritchard, appointed in Nov 2020, has a tenure of 2.83 years. total yearly compensation is CA$1.13M, comprised of 54.8% salary and 45.2% bonuses, including company stock and options. directly owns 0.041% of the company’s shares, worth $5.42K. The average tenure of the management team and the board of directors is 2.8 years and 4.3 years respectively.

Key information

Bruce Pritchard

Chief executive officer

CA$1.1m

Total compensation

CEO salary percentage54.8%
CEO tenure2.8yrs
CEO ownership0.04%
Management average tenure2.8yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Liminal transfers to Nasdaq Capital Market, gets more time to comply with listing rule

Sep 02

Liminal BioSciences ends CDMO agreement for $33M cost savings

Aug 25

Liminal BioSciences discontinues fezagepras development

Jul 21

FDA grants approval to Liminal BioSciences' Ryplazim treatment

Jun 04

Liminal shares slide after plans to stop fezagepras development

May 28

Liminal Biosciences subsidiary receives FDA nod for US-based plasma collection centre

Jan 12

Liminal BioSciences Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 13

FDA extends review period for Liminal Bio's Ryplazim application

Nov 09

CEO Compensation Analysis

How has Bruce Pritchard's remuneration changed compared to Liminal BioSciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-CA$28m

Mar 31 2023n/an/a

-CA$26m

Dec 31 2022CA$1mCA$618k

-CA$29m

Sep 30 2022n/an/a

-CA$31m

Jun 30 2022n/an/a

-CA$36m

Mar 31 2022n/an/a

-CA$42m

Dec 31 2021CA$1mCA$591k

-CA$44m

Sep 30 2021n/an/a

-CA$48m

Jun 30 2021n/an/a

-CA$49m

Mar 31 2021n/an/a

-CA$35m

Dec 31 2020CA$2mCA$556k

-CA$48m

Sep 30 2020n/an/a

-CA$75m

Jun 30 2020n/an/a

-CA$94m

Mar 31 2020n/an/a

-CA$232m

Dec 31 2019CA$5mCA$563k

-CA$150m

Sep 30 2019n/an/a

-CA$299m

Jun 30 2019n/an/a

-CA$298m

Mar 31 2019n/an/a

-CA$194m

Dec 31 2018CA$1mCA$575k

-CA$197m

Sep 30 2018n/an/a

-CA$131m

Jun 30 2018n/an/a

-CA$118m

Mar 31 2018n/an/a

-CA$115m

Dec 31 2017CA$3mCA$526k

-CA$112m

Sep 30 2017n/an/a

-CA$109m

Jun 30 2017n/an/a

-CA$119m

Mar 31 2017n/an/a

-CA$112m

Dec 31 2016CA$2mCA$531k

-CA$101m

Compensation vs Market: Bruce's total compensation ($USD838.13K) is about average for companies of similar size in the US market ($USD766.41K).

Compensation vs Earnings: Bruce's compensation has increased whilst the company is unprofitable.

CEO

Bruce Pritchard (49 yo)

2.8yrs

Tenure

CA$1,127,987

Compensation

Mr. Bruce Pritchard, BA, CA, FioD, served as Principal Financial Officer at Liminal BioSciences Inc. since September 3, 2021. Mr. Pritchard served as Chief Operating Officer of Small Molecule Therapeutics...

Leadership Team

NamePositionTenureCompensationOwnership
Bruce Pritchard
Chief Executive Officer2.8yrsCA$1.13m0.041%
$ 5.4k
Patrick Sartore
President2.8yrsCA$866.09k0.0098%
$ 1.3k
Gary Bridger
Interim Chief Scientific Officer & Non-Independent Directorless than a yearCA$428.33kno data
Marie Iskra
Corporate Secretary & General Counsel4yrsCA$637.35kno data
N. Rusaw
Chief Financial Officer1.5yrsno datano data
Shrinal Inamdar
Manager of Investor Relations & Communicationsno datano datano data
Steven Burton
President of Prometic Bioseparations Ltdno dataCA$258.74kno data

2.8yrs

Average Tenure

49yo

Average Age

Experienced Management: LMNL's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gary Bridger
Interim Chief Scientific Officer & Non-Independent Director4.3yrsCA$428.33kno data
Aleksander Krstajic
Independent Chair of the Board3yrsCA$178.00kno data
Simon Best
Lead Independent Director9.3yrsCA$167.58k0.066%
$ 8.6k
Eugene Siklos
Non-Independent Director3yrsno datano data
Benny Soffer
Board Observer4.4yrsno datano data
Neil Klompas
Independent Director4.3yrsCA$132.23kno data
Timothy Wach
Independent Director4.3yrsCA$120.67k0.028%
$ 3.6k

4.3yrs

Average Tenure

59yo

Average Age

Experienced Board: LMNL's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/27 21:37
End of Day Share Price 2023/09/25 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Liminal BioSciences Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Doug CooperBeacon Securities Limited
Antonia BorovinaBloom Burton & Co.
Dewey SteadmanCanaccord Genuity